CN1060285A - 含氮非芳香杂环的稠环类似物 - Google Patents
含氮非芳香杂环的稠环类似物 Download PDFInfo
- Publication number
- CN1060285A CN1060285A CN91109446A CN91109446A CN1060285A CN 1060285 A CN1060285 A CN 1060285A CN 91109446 A CN91109446 A CN 91109446A CN 91109446 A CN91109446 A CN 91109446A CN 1060285 A CN1060285 A CN 1060285A
- Authority
- CN
- China
- Prior art keywords
- formula
- alkyl
- compound
- phenyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 title claims description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 187
- 238000006243 chemical reaction Methods 0.000 claims description 77
- 238000000034 method Methods 0.000 claims description 55
- 125000000217 alkyl group Chemical group 0.000 claims description 46
- 229910052739 hydrogen Inorganic materials 0.000 claims description 35
- 239000001257 hydrogen Substances 0.000 claims description 35
- -1 benzhydryl groups Chemical group 0.000 claims description 29
- 230000002829 reductive effect Effects 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 24
- 125000004432 carbon atom Chemical group C* 0.000 claims description 24
- 229910052799 carbon Inorganic materials 0.000 claims description 21
- 239000002253 acid Substances 0.000 claims description 20
- 150000001721 carbon Chemical group 0.000 claims description 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- 125000001424 substituent group Chemical group 0.000 claims description 17
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 13
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 239000001301 oxygen Substances 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 239000011593 sulfur Substances 0.000 claims description 12
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 11
- 150000002431 hydrogen Chemical class 0.000 claims description 11
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 150000003952 β-lactams Chemical class 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 239000011737 fluorine Chemical group 0.000 claims description 6
- 229910052731 fluorine Chemical group 0.000 claims description 6
- 125000002541 furyl group Chemical group 0.000 claims description 6
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 6
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 6
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 6
- 125000000335 thiazolyl group Chemical group 0.000 claims description 6
- 125000001544 thienyl group Chemical group 0.000 claims description 6
- 125000001425 triazolyl group Chemical group 0.000 claims description 6
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 238000006722 reduction reaction Methods 0.000 claims description 5
- 150000001408 amides Chemical class 0.000 claims description 4
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims description 4
- 238000006268 reductive amination reaction Methods 0.000 claims description 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 3
- 125000002837 carbocyclic group Chemical group 0.000 claims description 3
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 3
- 125000002971 oxazolyl group Chemical group 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 abstract description 8
- 230000004054 inflammatory process Effects 0.000 abstract description 8
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 104
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 55
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 54
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 50
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 48
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 46
- 201000010099 disease Diseases 0.000 description 38
- 239000011541 reaction mixture Substances 0.000 description 37
- 238000005481 NMR spectroscopy Methods 0.000 description 33
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 29
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 27
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 27
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 26
- 102100024304 Protachykinin-1 Human genes 0.000 description 26
- 101800003906 Substance P Proteins 0.000 description 26
- 239000000203 mixture Substances 0.000 description 25
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 241000124008 Mammalia Species 0.000 description 20
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- 239000003921 oil Substances 0.000 description 17
- 235000019198 oils Nutrition 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 239000010410 layer Substances 0.000 description 12
- 239000002798 polar solvent Substances 0.000 description 12
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 11
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
- 206010020751 Hypersensitivity Diseases 0.000 description 10
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 229960000583 acetic acid Drugs 0.000 description 9
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- PKZJLOCLABXVMC-UHFFFAOYSA-N 2-Methoxybenzaldehyde Chemical compound COC1=CC=CC=C1C=O PKZJLOCLABXVMC-UHFFFAOYSA-N 0.000 description 8
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 8
- 206010009887 colitis Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 208000033808 peripheral neuropathy Diseases 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 230000003042 antagnostic effect Effects 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 230000035484 reaction time Effects 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 208000019901 Anxiety disease Diseases 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 208000001640 Fibromyalgia Diseases 0.000 description 6
- 239000005909 Kieselgur Substances 0.000 description 6
- 208000019695 Migraine disease Diseases 0.000 description 6
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 6
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 208000028017 Psychotic disease Diseases 0.000 description 6
- 208000025747 Rheumatic disease Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000036506 anxiety Effects 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 206010027599 migraine Diseases 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 206010065040 AIDS dementia complex Diseases 0.000 description 5
- 208000007848 Alcoholism Diseases 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- 206010008334 Cervicobrachial syndrome Diseases 0.000 description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 5
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 5
- 206010068319 Oropharyngeal pain Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 201000007100 Pharyngitis Diseases 0.000 description 5
- 201000004681 Psoriasis Diseases 0.000 description 5
- 241000159243 Toxicodendron radicans Species 0.000 description 5
- 201000007930 alcohol dependence Diseases 0.000 description 5
- 208000026935 allergic disease Diseases 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 5
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003638 chemical reducing agent Substances 0.000 description 5
- 235000019788 craving Nutrition 0.000 description 5
- 230000004064 dysfunction Effects 0.000 description 5
- 230000002327 eosinophilic effect Effects 0.000 description 5
- 208000006275 fascioliasis Diseases 0.000 description 5
- 230000009610 hypersensitivity Effects 0.000 description 5
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 5
- 239000002808 molecular sieve Substances 0.000 description 5
- 201000006417 multiple sclerosis Diseases 0.000 description 5
- 230000002981 neuropathic effect Effects 0.000 description 5
- 201000001119 neuropathy Diseases 0.000 description 5
- 230000007823 neuropathy Effects 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 206010039083 rhinitis Diseases 0.000 description 5
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 230000002455 vasospastic effect Effects 0.000 description 5
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- 208000027932 Collagen disease Diseases 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000006806 disease prevention Effects 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 239000012442 inert solvent Substances 0.000 description 4
- 230000007830 nerve conduction Effects 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 230000000392 somatic effect Effects 0.000 description 4
- 239000003890 substance P antagonist Substances 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- GYTDJCTUFWFXBE-UHFFFAOYSA-M (2,2,2-trifluoroacetyl)oxymercury Chemical compound [Hg+].[O-]C(=O)C(F)(F)F GYTDJCTUFWFXBE-UHFFFAOYSA-M 0.000 description 3
- NLHOHSTYGBILDW-BEEDKBRMSA-N (3s,4r)-1-[tert-butyl(dimethyl)silyl]-3-cyclopent-2-en-1-yl-4-phenylazetidin-2-one Chemical compound C1([C@H]2[C@@H](N(C2=O)[Si](C)(C)C(C)(C)C)C=2C=CC=CC=2)CCC=C1 NLHOHSTYGBILDW-BEEDKBRMSA-N 0.000 description 3
- PEZNEXFPRSOYPL-UHFFFAOYSA-N (bis(trifluoroacetoxy)iodo)benzene Chemical compound FC(F)(F)C(=O)OI(OC(=O)C(F)(F)F)C1=CC=CC=C1 PEZNEXFPRSOYPL-UHFFFAOYSA-N 0.000 description 3
- DQKJIOWCDBNSDR-UHFFFAOYSA-N 4-benzhydryl-3-azabicyclo[4.1.0]heptan-5-ol Chemical compound OC1C2CC2CNC1C(C=1C=CC=CC=1)C1=CC=CC=C1 DQKJIOWCDBNSDR-UHFFFAOYSA-N 0.000 description 3
- NQJIUZPYBZOGKL-UHFFFAOYSA-N 4-benzhydryl-3-azabicyclo[4.1.0]heptan-5-one Chemical compound O=C1C2CC2CNC1C(C=1C=CC=CC=1)C1=CC=CC=C1 NQJIUZPYBZOGKL-UHFFFAOYSA-N 0.000 description 3
- DELMNZCZSVHTAK-UHFFFAOYSA-N 4-benzhydryl-n-[(2-methoxyphenyl)methyl]-3-azabicyclo[4.1.0]heptan-5-amine Chemical compound COC1=CC=CC=C1CNC1C(C(C=2C=CC=CC=2)C=2C=CC=CC=2)NCC2CC21 DELMNZCZSVHTAK-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 208000004232 Enteritis Diseases 0.000 description 3
- 206010039710 Scleroderma Diseases 0.000 description 3
- 102000003141 Tachykinin Human genes 0.000 description 3
- WOMMBEYPWVELIE-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] 2,2,2-trifluoroacetate Chemical compound CC(C)(C)[Si](C)(C)OC(=O)C(F)(F)F WOMMBEYPWVELIE-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000006286 aqueous extract Substances 0.000 description 3
- 150000007514 bases Chemical class 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- YTJXGDYAEOTOCG-UHFFFAOYSA-N lithium;di(propan-2-yl)azanide;oxolane Chemical compound [Li+].C1CCOC1.CC(C)[N-]C(C)C YTJXGDYAEOTOCG-UHFFFAOYSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 3
- 229910003446 platinum oxide Inorganic materials 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 108060008037 tachykinin Proteins 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 3
- OKHIQWVGAJUEIY-GIQPFHSMSA-N (3s,4r)-n-[(2-methoxyphenyl)methyl]-3-phenyl-1,2,3,4-tetrahydroisoquinolin-4-amine;dihydrochloride Chemical compound Cl.Cl.COC1=CC=CC=C1CN[C@@H]1C2=CC=CC=C2CN[C@H]1C1=CC=CC=C1 OKHIQWVGAJUEIY-GIQPFHSMSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical compound O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012259 ether extract Substances 0.000 description 2
- DLLJVQNYBYOKGS-UHFFFAOYSA-N ethoxyethane;pentane Chemical compound CCCCC.CCOCC DLLJVQNYBYOKGS-UHFFFAOYSA-N 0.000 description 2
- ATUPEWQJOFWXMI-UHFFFAOYSA-N ethyl 2-phenylquinoline-3-carboxylate Chemical compound CCOC(=O)C1=CC2=CC=CC=C2N=C1C1=CC=CC=C1 ATUPEWQJOFWXMI-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- ZWFGMCQXBJCHNL-UHFFFAOYSA-N n-[(2,5-dimethoxyphenyl)methyl]-3-phenyl-2,3,4,5,5a,6,7,8,9,9a-decahydro-1h-benzo[c]azepin-4-amine Chemical compound COC1=CC=C(OC)C(CNC2C(NCC3CCCCC3C2)C=2C=CC=CC=2)=C1 ZWFGMCQXBJCHNL-UHFFFAOYSA-N 0.000 description 2
- XUXSAAVKSNQVRW-UHFFFAOYSA-N n-[(2,5-dimethoxyphenyl)methyl]-4-phenyl-2,3,4,5,5a,6,7,8,9,9a-decahydro-1h-benzo[d]azepin-5-amine Chemical compound COC1=CC=C(OC)C(CNC2C(NCCC3CCCCC32)C=2C=CC=CC=2)=C1 XUXSAAVKSNQVRW-UHFFFAOYSA-N 0.000 description 2
- HNXPMXNINBNHHK-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-2-phenyl-1,2,3,4,4a,5,6,7,8,8a-decahydroquinolin-3-amine Chemical compound COC1=CC=CC=C1CNC1C(C=2C=CC=CC=2)NC2CCCCC2C1 HNXPMXNINBNHHK-UHFFFAOYSA-N 0.000 description 2
- ILSLMEABUVUVJD-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-3-phenyl-2,3,4,5,5a,6,7,8,9,9a-decahydro-1h-benzo[c]azepin-4-amine Chemical compound COC1=CC=CC=C1CNC1C(C=2C=CC=CC=2)NCC2CCCCC2C1 ILSLMEABUVUVJD-UHFFFAOYSA-N 0.000 description 2
- QKUUVTGUMJCJOM-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-4-phenyl-2,3,4,5,5a,6,7,8,9,9a-decahydro-1h-benzo[d]azepin-5-amine Chemical compound COC1=CC=CC=C1CNC1C(C=2C=CC=CC=2)NCCC2CCCCC21 QKUUVTGUMJCJOM-UHFFFAOYSA-N 0.000 description 2
- ZUCXICPOVPIAAP-UHFFFAOYSA-N n-[(5-chloro-2-methoxyphenyl)methyl]-3-phenyl-2,3,4,5,5a,6,7,8,9,9a-decahydro-1h-benzo[c]azepin-4-amine Chemical compound COC1=CC=C(Cl)C=C1CNC1C(C=2C=CC=CC=2)NCC2CCCCC2C1 ZUCXICPOVPIAAP-UHFFFAOYSA-N 0.000 description 2
- JLUUPWJYTFAMII-UHFFFAOYSA-N n-[(5-chloro-2-methoxyphenyl)methyl]-4-phenyl-2,3,4,5,5a,6,7,8,9,9a-decahydro-1h-benzo[d]azepin-5-amine Chemical compound COC1=CC=C(Cl)C=C1CNC1C(C=2C=CC=CC=2)NCCC2CCCCC21 JLUUPWJYTFAMII-UHFFFAOYSA-N 0.000 description 2
- VVXIQWIOSQRVKV-UHFFFAOYSA-N n-[(5-fluoro-2-methoxyphenyl)methyl]-3-phenyl-2,3,4,5,5a,6,7,8,9,9a-decahydro-1h-benzo[c]azepin-4-amine Chemical compound COC1=CC=C(F)C=C1CNC1C(C=2C=CC=CC=2)NCC2CCCCC2C1 VVXIQWIOSQRVKV-UHFFFAOYSA-N 0.000 description 2
- BSOUAJXQJSBHOK-UHFFFAOYSA-N n-[(5-fluoro-2-methoxyphenyl)methyl]-4-phenyl-2,3,4,5,5a,6,7,8,9,9a-decahydro-1h-benzo[d]azepin-5-amine Chemical compound COC1=CC=C(F)C=C1CNC1C(C=2C=CC=CC=2)NCCC2CCCCC21 BSOUAJXQJSBHOK-UHFFFAOYSA-N 0.000 description 2
- GHSMQGTUMSGGGO-UHFFFAOYSA-N n-[(5-tert-butyl-2-methoxyphenyl)methyl]-2-phenyl-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[b]pyrrol-3-amine Chemical compound COC1=CC=C(C(C)(C)C)C=C1CNC1C(C=2C=CC=CC=2)NC2CCCC21 GHSMQGTUMSGGGO-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 208000027232 peripheral nervous system disease Diseases 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- AFDMODCXODAXLC-UHFFFAOYSA-N phenylmethanimine Chemical compound N=CC1=CC=CC=C1 AFDMODCXODAXLC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- VDNFXIRVUATOEG-UHFFFAOYSA-N (2-nitro-1-phenylethyl)benzene Chemical compound C=1C=CC=CC=1C(C[N+](=O)[O-])C1=CC=CC=C1 VDNFXIRVUATOEG-UHFFFAOYSA-N 0.000 description 1
- MRXDGVXSWIXTQL-HYHFHBMOSA-N (2s)-2-[[(1s)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C1NC(N)=NCC1)C(O)=O)C1=CC=CC=C1 MRXDGVXSWIXTQL-HYHFHBMOSA-N 0.000 description 1
- BNVSOBVEYPBNFE-PKTZIBPZSA-N (3s,4r)-4-[(2-methoxyphenyl)methylamino]-2-methyl-3-phenyl-3,4-dihydroisoquinolin-1-one Chemical compound COC1=CC=CC=C1CN[C@@H]1C2=CC=CC=C2C(=O)N(C)[C@H]1C1=CC=CC=C1 BNVSOBVEYPBNFE-PKTZIBPZSA-N 0.000 description 1
- YHHXYOYYXFVZIM-FCHUYYIVSA-N (3s,4r)-4-[(2-methoxyphenyl)methylamino]-3-phenyl-3,4-dihydro-2h-isoquinolin-1-one Chemical compound COC1=CC=CC=C1CN[C@@H]1C2=CC=CC=C2C(=O)N[C@H]1C1=CC=CC=C1 YHHXYOYYXFVZIM-FCHUYYIVSA-N 0.000 description 1
- DJFKEDGMUKFZFG-CABCVRRESA-N (3s,4r)-4-amino-2-methyl-3-phenyl-3,4-dihydroisoquinolin-1-one Chemical compound C1([C@@H]2N(C(C3=CC=CC=C3[C@H]2N)=O)C)=CC=CC=C1 DJFKEDGMUKFZFG-CABCVRRESA-N 0.000 description 1
- OXSWCWZKKNQMHI-KGLIPLIRSA-N (3s,4r)-4-amino-3-phenyl-3,4-dihydro-2h-isoquinolin-1-one Chemical compound C1([C@H]2[C@@H](C3=CC=CC=C3C(=O)N2)N)=CC=CC=C1 OXSWCWZKKNQMHI-KGLIPLIRSA-N 0.000 description 1
- CYAMCEFBULMVSA-RPWUZVMVSA-N (3s,4r)-n-[(2-methoxyphenyl)methyl]-2-methyl-3-phenyl-3,4-dihydro-1h-isoquinolin-4-amine Chemical compound COC1=CC=CC=C1CN[C@@H]1C2=CC=CC=C2CN(C)[C@H]1C1=CC=CC=C1 CYAMCEFBULMVSA-RPWUZVMVSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- SPFGELQLVHNQFN-UHFFFAOYSA-N 2-benzhydryl-n-[(2,5-dimethoxyphenyl)methyl]-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[b]pyrrol-3-amine Chemical compound COC1=CC=C(OC)C(CNC2C(NC3CCCC32)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SPFGELQLVHNQFN-UHFFFAOYSA-N 0.000 description 1
- LLGKAEDNXZTINQ-UHFFFAOYSA-N 2-benzhydryl-n-[(2-methoxyphenyl)methyl]-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[b]pyrrol-3-amine Chemical compound COC1=CC=CC=C1CNC1C(C(C=2C=CC=CC=2)C=2C=CC=CC=2)NC2CCCC21 LLGKAEDNXZTINQ-UHFFFAOYSA-N 0.000 description 1
- MZESMIOQGZRESB-UHFFFAOYSA-N 2-benzhydryl-n-[(5-chloro-2-methoxyphenyl)methyl]-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[b]pyrrol-3-amine Chemical compound COC1=CC=C(Cl)C=C1CNC1C2CCCC2NC1C(C=1C=CC=CC=1)C1=CC=CC=C1 MZESMIOQGZRESB-UHFFFAOYSA-N 0.000 description 1
- OHAOQIOOFXTHAC-UHFFFAOYSA-N 2-benzhydryl-n-[(5-ethyl-2-methoxyphenyl)methyl]-2,3,3a,4,6,6a-hexahydro-1h-furo[3,4-b]pyrrol-3-amine Chemical compound CCC1=CC=C(OC)C(CNC2C(NC3COCC32)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 OHAOQIOOFXTHAC-UHFFFAOYSA-N 0.000 description 1
- NQQPRZVMXLTGMY-UHFFFAOYSA-N 2-benzhydryl-n-[(5-fluoro-2-methoxyphenyl)methyl]-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[b]pyrrol-3-amine Chemical compound COC1=CC=C(F)C=C1CNC1C2CCCC2NC1C(C=1C=CC=CC=1)C1=CC=CC=C1 NQQPRZVMXLTGMY-UHFFFAOYSA-N 0.000 description 1
- DYBRDEYEILEMPA-UHFFFAOYSA-N 2-benzhydryl-n-[(5-tert-butyl-2-methoxyphenyl)methyl]-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[b]pyrrol-3-amine Chemical compound COC1=CC=C(C(C)(C)C)C=C1CNC1C(C(C=2C=CC=CC=2)C=2C=CC=CC=2)NC2CCCC21 DYBRDEYEILEMPA-UHFFFAOYSA-N 0.000 description 1
- WTGRLMMESTUCSJ-UHFFFAOYSA-N 2-benzhydryl-n-[(5-tert-butyl-2-methoxyphenyl)methyl]-1,2,3,4,4a,5,6,7,8,8a-decahydroquinolin-3-amine Chemical compound COC1=CC=C(C(C)(C)C)C=C1CNC1C(C(C=2C=CC=CC=2)C=2C=CC=CC=2)NC2CCCCC2C1 WTGRLMMESTUCSJ-UHFFFAOYSA-N 0.000 description 1
- ZBZDYWGIGQEPFM-UHFFFAOYSA-N 2-phenyl-2,3,3a,4,5,6-hexahydro-1H-cyclopenta[b]pyrrol-6a-amine Chemical compound NC12NC(CC2CCC1)C1=CC=CC=C1 ZBZDYWGIGQEPFM-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- URFQUCTUEZXBHA-UHFFFAOYSA-N 4-benzhydryl-3-azabicyclo[4.1.0]heptan-5-amine Chemical compound NC1C2CC2CNC1C(C=1C=CC=CC=1)C1=CC=CC=C1 URFQUCTUEZXBHA-UHFFFAOYSA-N 0.000 description 1
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OLVPQBGMUGIKIW-UHFFFAOYSA-N Chymostatin Natural products C=1C=CC=CC=1CC(C=O)NC(=O)C(C(C)CC)NC(=O)C(C1NC(N)=NCC1)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 OLVPQBGMUGIKIW-UHFFFAOYSA-N 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- HXTGGPKOEKKUQO-VQHVLOKHSA-N N-BENZYLIDENEMETHYLAMINE Chemical compound C\N=C\C1=CC=CC=C1 HXTGGPKOEKKUQO-VQHVLOKHSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000007124 Tachykinin Receptors Human genes 0.000 description 1
- 108010072901 Tachykinin Receptors Proteins 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- WSEYRYIQSMUYMG-UHFFFAOYSA-N [3-iodo-2-(2,2,2-trifluoroacetyl)oxyphenyl] 2,2,2-trifluoroacetate Chemical compound FC(F)(F)C(=O)OC1=CC=CC(I)=C1OC(=O)C(F)(F)F WSEYRYIQSMUYMG-UHFFFAOYSA-N 0.000 description 1
- DSVGQVZAZSZEEX-UHFFFAOYSA-N [C].[Pt] Chemical compound [C].[Pt] DSVGQVZAZSZEEX-UHFFFAOYSA-N 0.000 description 1
- WASQQWUXKQJGAB-UHFFFAOYSA-N [Pb].CC(C)(O)C Chemical compound [Pb].CC(C)(O)C WASQQWUXKQJGAB-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- KTLFENNEPHBKJD-UHFFFAOYSA-K benzyl(trimethyl)azanium;tribromide Chemical compound [Br-].[Br-].[Br-].C[N+](C)(C)CC1=CC=CC=C1.C[N+](C)(C)CC1=CC=CC=C1.C[N+](C)(C)CC1=CC=CC=C1 KTLFENNEPHBKJD-UHFFFAOYSA-K 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 description 1
- 108010086192 chymostatin Proteins 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-M cyclopropanecarboxylate Chemical compound [O-]C(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-M 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- LBAQSKZHMLAFHH-UHFFFAOYSA-N ethoxyethane;hydron;chloride Chemical compound Cl.CCOCC LBAQSKZHMLAFHH-UHFFFAOYSA-N 0.000 description 1
- NWDXPAPATGRXKV-UHFFFAOYSA-N ethyl 2-phenyl-1,2,3,4,4a,5,6,7,8,8a-decahydroquinoline-3-carboxylate Chemical compound CCOC(=O)C1CC2CCCCC2NC1C1=CC=CC=C1 NWDXPAPATGRXKV-UHFFFAOYSA-N 0.000 description 1
- BMDYXUJHUVFCJK-UHFFFAOYSA-N ethyl 2-phenyl-1,2,3,4-tetrahydroquinoline-3-carboxylate Chemical compound CCOC(=O)C1CC2=CC=CC=C2NC1C1=CC=CC=C1 BMDYXUJHUVFCJK-UHFFFAOYSA-N 0.000 description 1
- NYXATQKDISMJBK-UHFFFAOYSA-N ethyl 3-anilino-3-phenylprop-2-enoate Chemical group C=1C=CC=CC=1C(=CC(=O)OCC)NC1=CC=CC=C1 NYXATQKDISMJBK-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- 230000035873 hypermotility Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229960002523 mercuric chloride Drugs 0.000 description 1
- 150000002730 mercury Chemical class 0.000 description 1
- BRMYZIKAHFEUFJ-UHFFFAOYSA-L mercury diacetate Chemical compound CC(=O)O[Hg]OC(C)=O BRMYZIKAHFEUFJ-UHFFFAOYSA-L 0.000 description 1
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 1
- DDVCINFVCJPXDZ-UHFFFAOYSA-N methyl 2-cyclopent-2-en-1-yl-3-phenyl-3-(phenylmethoxycarbonylamino)propanoate Chemical compound C1CC=CC1C(C(=O)OC)C(C=1C=CC=CC=1)NC(=O)OCC1=CC=CC=C1 DDVCINFVCJPXDZ-UHFFFAOYSA-N 0.000 description 1
- NGMGARDIUOMOGH-UHFFFAOYSA-N methyl 2-cyclopent-2-en-1-ylacetate Chemical compound COC(=O)CC1CCC=C1 NGMGARDIUOMOGH-UHFFFAOYSA-N 0.000 description 1
- GXHTYYWMPPPKRZ-UHFFFAOYSA-N methyl 2-propylhexanoate Chemical compound CCCCC(CCC)C(=O)OC GXHTYYWMPPPKRZ-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- HYNHAHDXRXYAQY-UHFFFAOYSA-N n-[(2,5-dimethoxyphenyl)methyl]-2-phenyl-1,2,3,4,4a,5,7,7a-octahydrofuro[3,4-b]pyridin-3-amine Chemical compound COC1=CC=C(OC)C(CNC2C(NC3COCC3C2)C=2C=CC=CC=2)=C1 HYNHAHDXRXYAQY-UHFFFAOYSA-N 0.000 description 1
- IUZFHYFVLSKRIP-UHFFFAOYSA-N n-[(2,5-dimethoxyphenyl)methyl]-2-phenyl-1,2,3,4,5,5a,6,7,8,8a-decahydrocyclopenta[b]azepin-3-amine Chemical compound COC1=CC=C(OC)C(CNC2C(NC3CCCC3CC2)C=2C=CC=CC=2)=C1 IUZFHYFVLSKRIP-UHFFFAOYSA-N 0.000 description 1
- KFWNCOADAURTHA-UHFFFAOYSA-N n-[(2,5-dimethoxyphenyl)methyl]-2-phenyl-2,3,3a,4,5,6,7,7a-octahydro-1h-indol-3-amine Chemical compound COC1=CC=C(OC)C(CNC2C(NC3CCCCC32)C=2C=CC=CC=2)=C1 KFWNCOADAURTHA-UHFFFAOYSA-N 0.000 description 1
- AZKMGBGYVHFRJM-UHFFFAOYSA-N n-[(2,5-dimethoxyphenyl)methyl]-2-phenyl-2,3,4,4a,5,6,7,7a-octahydro-1h-cyclopenta[b]pyridin-3-amine Chemical compound COC1=CC=C(OC)C(CNC2C(NC3CCCC3C2)C=2C=CC=CC=2)=C1 AZKMGBGYVHFRJM-UHFFFAOYSA-N 0.000 description 1
- IJLUNQWEYSNMDJ-UHFFFAOYSA-N n-[(2,5-dimethoxyphenyl)methyl]-2-phenyl-2,3,4,4a,5,6,7,8,9,9a-decahydro-1h-cyclohepta[b]pyridin-3-amine Chemical compound COC1=CC=C(OC)C(CNC2C(NC3CCCCCC3C2)C=2C=CC=CC=2)=C1 IJLUNQWEYSNMDJ-UHFFFAOYSA-N 0.000 description 1
- DZAGECKNCGLOGD-UHFFFAOYSA-N n-[(2,5-dimethoxyphenyl)methyl]-2-phenyl-2,3,4,5,5a,6,7,8,9,9a-decahydro-1h-benzo[b]azepin-3-amine Chemical compound COC1=CC=C(OC)C(CNC2C(NC3CCCCC3CC2)C=2C=CC=CC=2)=C1 DZAGECKNCGLOGD-UHFFFAOYSA-N 0.000 description 1
- DPRXQXQLIFYYIE-UHFFFAOYSA-N n-[(2,5-dimethoxyphenyl)methyl]-3-phenyl-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinolin-4-amine Chemical compound COC1=CC=C(OC)C(CNC2C(NCC3CCCCC32)C=2C=CC=CC=2)=C1 DPRXQXQLIFYYIE-UHFFFAOYSA-N 0.000 description 1
- IHHZMHHEQVMVTN-UHFFFAOYSA-N n-[(2,5-dimethoxyphenyl)methyl]-3-phenyl-1,2,3,4,5,5a,6,7,8,8a-decahydrocyclopenta[c]azepin-4-amine Chemical compound COC1=CC=C(OC)C(CNC2C(NCC3CCCC3C2)C=2C=CC=CC=2)=C1 IHHZMHHEQVMVTN-UHFFFAOYSA-N 0.000 description 1
- NMPDACOIVIXQBI-UHFFFAOYSA-N n-[(2,5-dimethoxyphenyl)methyl]-3-phenyl-2,3,4,4a,5,6,7,7a-octahydro-1h-cyclopenta[c]pyridin-4-amine Chemical compound COC1=CC=C(OC)C(CNC2C(NCC3CCCC32)C=2C=CC=CC=2)=C1 NMPDACOIVIXQBI-UHFFFAOYSA-N 0.000 description 1
- VYMDHFHHDDSYNQ-UHFFFAOYSA-N n-[(2,5-dimethoxyphenyl)methyl]-3-phenyl-2,3,4,4a,5,6,7,8,9,9a-decahydro-1h-cyclohepta[c]pyridin-4-amine Chemical compound COC1=CC=C(OC)C(CNC2C(NCC3CCCCCC32)C=2C=CC=CC=2)=C1 VYMDHFHHDDSYNQ-UHFFFAOYSA-N 0.000 description 1
- CDNVGCYOMBIJLI-UHFFFAOYSA-N n-[(2,5-dimethoxyphenyl)methyl]-4-phenyl-5-azabicyclo[5.1.0]octan-3-amine Chemical compound COC1=CC=C(OC)C(CNC2C(NCC3CC3C2)C=2C=CC=CC=2)=C1 CDNVGCYOMBIJLI-UHFFFAOYSA-N 0.000 description 1
- CSHAAGINYVNYIV-UHFFFAOYSA-N n-[(2,5-dimethoxyphenyl)methyl]-5-phenyl-6-azabicyclo[5.5.0]dodecan-4-amine Chemical compound COC1=CC=C(OC)C(CNC2C(NC3CCCCCC3CC2)C=2C=CC=CC=2)=C1 CSHAAGINYVNYIV-UHFFFAOYSA-N 0.000 description 1
- NABYUCIUONVWHN-UHFFFAOYSA-N n-[(2-methoxy-5-phenylphenyl)methyl]-2-phenyl-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[b]pyrrol-3-amine Chemical compound COC1=CC=C(C=2C=CC=CC=2)C=C1CNC1C2CCCC2NC1C1=CC=CC=C1 NABYUCIUONVWHN-UHFFFAOYSA-N 0.000 description 1
- FXIAHKWOLSMKTH-UHFFFAOYSA-N n-[(2-methoxy-5-propan-2-ylphenyl)methyl]-2-phenyl-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[b]pyrrol-3-amine Chemical compound COC1=CC=C(C(C)C)C=C1CNC1C(C=2C=CC=CC=2)NC2CCCC21 FXIAHKWOLSMKTH-UHFFFAOYSA-N 0.000 description 1
- QFZCPLFRPKOALH-UHFFFAOYSA-N n-[(2-methoxy-5-propylphenyl)methyl]-2-phenyl-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[b]pyrrol-3-amine Chemical compound CCCC1=CC=C(OC)C(CNC2C(NC3CCCC32)C=2C=CC=CC=2)=C1 QFZCPLFRPKOALH-UHFFFAOYSA-N 0.000 description 1
- KLOBHAOGTVVDCI-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-2-phenyl-1,2,3,4,4a,5,6,7,8,8a-decahydroquinolin-3-amine;hydrochloride Chemical compound Cl.COC1=CC=CC=C1CNC1C(C=2C=CC=CC=2)NC2CCCCC2C1 KLOBHAOGTVVDCI-UHFFFAOYSA-N 0.000 description 1
- FMPROYLFPOKHPU-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-2-phenyl-1,2,3,4,4a,5,7,7a-octahydrofuro[3,4-b]pyridin-3-amine Chemical compound COC1=CC=CC=C1CNC1C(C=2C=CC=CC=2)NC2COCC2C1 FMPROYLFPOKHPU-UHFFFAOYSA-N 0.000 description 1
- CUBHXDRKTDWARU-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-2-phenyl-1,2,3,4,5,5a,6,7,8,8a-decahydrocyclopenta[b]azepin-3-amine Chemical compound COC1=CC=CC=C1CNC1C(C=2C=CC=CC=2)NC2CCCC2CC1 CUBHXDRKTDWARU-UHFFFAOYSA-N 0.000 description 1
- RAPYEQWTEDGYLB-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-2-phenyl-1,2,3,4-tetrahydroquinolin-3-amine Chemical compound COC1=CC=CC=C1CNC1C(C=2C=CC=CC=2)NC2=CC=CC=C2C1 RAPYEQWTEDGYLB-UHFFFAOYSA-N 0.000 description 1
- QKONCIOXPYTGQD-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-2-phenyl-2,3,3a,4,5,6,7,7a-octahydro-1h-indol-3-amine Chemical compound COC1=CC=CC=C1CNC1C(C=2C=CC=CC=2)NC2CCCCC21 QKONCIOXPYTGQD-UHFFFAOYSA-N 0.000 description 1
- WYCTVCBAOFHUNY-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-2-phenyl-2,3,3a,4,6,6a-hexahydro-1h-furo[3,4-b]pyrrol-3-amine Chemical compound COC1=CC=CC=C1CNC1C(C=2C=CC=CC=2)NC2COCC21 WYCTVCBAOFHUNY-UHFFFAOYSA-N 0.000 description 1
- MPQUQCGTPGZXAC-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-2-phenyl-2,3,4,4a,5,6,7,7a-octahydro-1h-cyclopenta[b]pyridin-3-amine Chemical compound COC1=CC=CC=C1CNC1C(C=2C=CC=CC=2)NC2CCCC2C1 MPQUQCGTPGZXAC-UHFFFAOYSA-N 0.000 description 1
- OUBYZYSWEBAXOE-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-2-phenyl-2,3,4,4a,5,6,7,8,9,9a-decahydro-1h-cyclohepta[b]pyridin-3-amine Chemical compound COC1=CC=CC=C1CNC1C(C=2C=CC=CC=2)NC2CCCCCC2C1 OUBYZYSWEBAXOE-UHFFFAOYSA-N 0.000 description 1
- SALZJDPHLYVTDK-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-2-phenyl-2,3,4,5,5a,6,7,8,9,9a-decahydro-1h-benzo[b]azepin-3-amine Chemical compound COC1=CC=CC=C1CNC1C(C=2C=CC=CC=2)NC2CCCCC2CC1 SALZJDPHLYVTDK-UHFFFAOYSA-N 0.000 description 1
- IHEWXEFIDMEOLM-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-3-phenyl-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinolin-4-amine Chemical compound COC1=CC=CC=C1CNC1C(C=2C=CC=CC=2)NCC2CCCCC21 IHEWXEFIDMEOLM-UHFFFAOYSA-N 0.000 description 1
- MIWKBPODMIPLJR-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-3-phenyl-1,2,3,4,5,5a,6,7,8,8a-decahydrocyclopenta[c]azepin-4-amine Chemical compound COC1=CC=CC=C1CNC1C(C=2C=CC=CC=2)NCC2CCCC2C1 MIWKBPODMIPLJR-UHFFFAOYSA-N 0.000 description 1
- GIVURZZXLVZCHH-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-3-phenyl-2,3,4,4a,5,6,7,7a-octahydro-1h-cyclopenta[c]pyridin-4-amine Chemical compound COC1=CC=CC=C1CNC1C(C=2C=CC=CC=2)NCC2CCCC21 GIVURZZXLVZCHH-UHFFFAOYSA-N 0.000 description 1
- UGVUDZBXFZVTFU-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-3-phenyl-2,3,4,4a,5,6,7,8,9,9a-decahydro-1h-cyclohepta[c]pyridin-4-amine Chemical compound COC1=CC=CC=C1CNC1C(C=2C=CC=CC=2)NCC2CCCCCC21 UGVUDZBXFZVTFU-UHFFFAOYSA-N 0.000 description 1
- JUJGEHZEQYIZQH-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-4-phenyl-5-azabicyclo[5.1.0]octan-3-amine Chemical compound COC1=CC=CC=C1CNC1C(C=2C=CC=CC=2)NCC2CC2C1 JUJGEHZEQYIZQH-UHFFFAOYSA-N 0.000 description 1
- XOIDKSSPABOTRM-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-5-phenyl-3,3a,4,5,6,6a-hexahydro-2h-furo[2,3-b]pyrrol-4-amine Chemical compound COC1=CC=CC=C1CNC1C(C=2C=CC=CC=2)NC2OCCC21 XOIDKSSPABOTRM-UHFFFAOYSA-N 0.000 description 1
- IYFBKTHRJHNFQW-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-5-phenyl-6-azabicyclo[5.5.0]dodecan-4-amine Chemical compound COC1=CC=CC=C1CNC1C(C=2C=CC=CC=2)NC2CCCCCC2CC1 IYFBKTHRJHNFQW-UHFFFAOYSA-N 0.000 description 1
- BBDHIOFUUQJFIV-UHFFFAOYSA-N n-[(5-chloro-2-methoxyphenyl)methyl]-2-phenyl-1,2,3,4,4a,5,7,7a-octahydrofuro[3,4-b]pyridin-3-amine Chemical compound COC1=CC=C(Cl)C=C1CNC1C(C=2C=CC=CC=2)NC2COCC2C1 BBDHIOFUUQJFIV-UHFFFAOYSA-N 0.000 description 1
- OSCXIYDAGZWDJX-UHFFFAOYSA-N n-[(5-chloro-2-methoxyphenyl)methyl]-2-phenyl-1,2,3,4,5,5a,6,7,8,8a-decahydrocyclopenta[b]azepin-3-amine Chemical compound COC1=CC=C(Cl)C=C1CNC1C(C=2C=CC=CC=2)NC2CCCC2CC1 OSCXIYDAGZWDJX-UHFFFAOYSA-N 0.000 description 1
- CCLMHHFMOYOEGE-UHFFFAOYSA-N n-[(5-chloro-2-methoxyphenyl)methyl]-2-phenyl-2,3,3a,4,5,6,7,7a-octahydro-1h-indol-3-amine Chemical compound COC1=CC=C(Cl)C=C1CNC1C(C=2C=CC=CC=2)NC2CCCCC21 CCLMHHFMOYOEGE-UHFFFAOYSA-N 0.000 description 1
- KFYOGAWWFMGIBU-UHFFFAOYSA-N n-[(5-chloro-2-methoxyphenyl)methyl]-2-phenyl-2,3,4,4a,5,6,7,7a-octahydro-1h-cyclopenta[b]pyridin-3-amine Chemical compound COC1=CC=C(Cl)C=C1CNC1C(C=2C=CC=CC=2)NC2CCCC2C1 KFYOGAWWFMGIBU-UHFFFAOYSA-N 0.000 description 1
- ILAZHHZPHQZLNO-UHFFFAOYSA-N n-[(5-chloro-2-methoxyphenyl)methyl]-2-phenyl-2,3,4,4a,5,6,7,8,9,9a-decahydro-1h-cyclohepta[b]pyridin-3-amine Chemical compound COC1=CC=C(Cl)C=C1CNC1C(C=2C=CC=CC=2)NC2CCCCCC2C1 ILAZHHZPHQZLNO-UHFFFAOYSA-N 0.000 description 1
- RXFAQFAPLMCKON-UHFFFAOYSA-N n-[(5-chloro-2-methoxyphenyl)methyl]-2-phenyl-2,3,4,5,5a,6,7,8,9,9a-decahydro-1h-benzo[b]azepin-3-amine Chemical compound COC1=CC=C(Cl)C=C1CNC1C(C=2C=CC=CC=2)NC2CCCCC2CC1 RXFAQFAPLMCKON-UHFFFAOYSA-N 0.000 description 1
- FWZFZNZGWJROJK-UHFFFAOYSA-N n-[(5-chloro-2-methoxyphenyl)methyl]-3-phenyl-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinolin-4-amine Chemical compound COC1=CC=C(Cl)C=C1CNC1C(C=2C=CC=CC=2)NCC2CCCCC21 FWZFZNZGWJROJK-UHFFFAOYSA-N 0.000 description 1
- LCCDECVJKCVWKE-UHFFFAOYSA-N n-[(5-chloro-2-methoxyphenyl)methyl]-3-phenyl-1,2,3,4,5,5a,6,7,8,8a-decahydrocyclopenta[c]azepin-4-amine Chemical compound COC1=CC=C(Cl)C=C1CNC1C(C=2C=CC=CC=2)NCC2CCCC2C1 LCCDECVJKCVWKE-UHFFFAOYSA-N 0.000 description 1
- AEVRCALLQOTKOO-UHFFFAOYSA-N n-[(5-chloro-2-methoxyphenyl)methyl]-3-phenyl-2,3,4,4a,5,6,7,7a-octahydro-1h-cyclopenta[c]pyridin-4-amine Chemical compound COC1=CC=C(Cl)C=C1CNC1C(C=2C=CC=CC=2)NCC2CCCC21 AEVRCALLQOTKOO-UHFFFAOYSA-N 0.000 description 1
- VUTKEBLOMMQZET-UHFFFAOYSA-N n-[(5-chloro-2-methoxyphenyl)methyl]-3-phenyl-2,3,4,4a,5,6,7,8,9,9a-decahydro-1h-cyclohepta[c]pyridin-4-amine Chemical compound COC1=CC=C(Cl)C=C1CNC1C(C=2C=CC=CC=2)NCC2CCCCCC21 VUTKEBLOMMQZET-UHFFFAOYSA-N 0.000 description 1
- FCETYEUUCFSDTO-UHFFFAOYSA-N n-[(5-chloro-2-methoxyphenyl)methyl]-4-phenyl-5-azabicyclo[5.1.0]octan-3-amine Chemical compound COC1=CC=C(Cl)C=C1CNC1C(C=2C=CC=CC=2)NCC2CC2C1 FCETYEUUCFSDTO-UHFFFAOYSA-N 0.000 description 1
- ZCQKZFABIGHJRK-UHFFFAOYSA-N n-[(5-chloro-2-methoxyphenyl)methyl]-5-phenyl-6-azabicyclo[5.5.0]dodecan-4-amine Chemical compound COC1=CC=C(Cl)C=C1CNC1C(C=2C=CC=CC=2)NC2CCCCCC2CC1 ZCQKZFABIGHJRK-UHFFFAOYSA-N 0.000 description 1
- YXNBEBNNJBBJNT-UHFFFAOYSA-N n-[(5-ethyl-2-methoxyphenyl)methyl]-2-phenyl-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[b]pyrrol-3-amine Chemical compound CCC1=CC=C(OC)C(CNC2C(NC3CCCC32)C=2C=CC=CC=2)=C1 YXNBEBNNJBBJNT-UHFFFAOYSA-N 0.000 description 1
- WKBYEZINRMTIGC-UHFFFAOYSA-N n-[(5-fluoro-2-methoxyphenyl)methyl]-2-phenyl-1,2,3,4,4a,5,7,7a-octahydrofuro[3,4-b]pyridin-3-amine Chemical compound COC1=CC=C(F)C=C1CNC1C(C=2C=CC=CC=2)NC2COCC2C1 WKBYEZINRMTIGC-UHFFFAOYSA-N 0.000 description 1
- BAMAYDLNMQHFCN-UHFFFAOYSA-N n-[(5-fluoro-2-methoxyphenyl)methyl]-2-phenyl-1,2,3,4,5,5a,6,7,8,8a-decahydrocyclopenta[b]azepin-3-amine Chemical compound COC1=CC=C(F)C=C1CNC1C(C=2C=CC=CC=2)NC2CCCC2CC1 BAMAYDLNMQHFCN-UHFFFAOYSA-N 0.000 description 1
- BMEBRDIVWSWKRM-UHFFFAOYSA-N n-[(5-fluoro-2-methoxyphenyl)methyl]-2-phenyl-2,3,3a,4,5,6,7,7a-octahydro-1h-indol-3-amine Chemical compound COC1=CC=C(F)C=C1CNC1C(C=2C=CC=CC=2)NC2CCCCC21 BMEBRDIVWSWKRM-UHFFFAOYSA-N 0.000 description 1
- IJIBIJNNRXLBHI-UHFFFAOYSA-N n-[(5-fluoro-2-methoxyphenyl)methyl]-2-phenyl-2,3,4,4a,5,6,7,7a-octahydro-1h-cyclopenta[b]pyridin-3-amine Chemical compound COC1=CC=C(F)C=C1CNC1C(C=2C=CC=CC=2)NC2CCCC2C1 IJIBIJNNRXLBHI-UHFFFAOYSA-N 0.000 description 1
- NHEGGUSCXQEJNO-UHFFFAOYSA-N n-[(5-fluoro-2-methoxyphenyl)methyl]-2-phenyl-2,3,4,4a,5,6,7,8,9,9a-decahydro-1h-cyclohepta[b]pyridin-3-amine Chemical compound COC1=CC=C(F)C=C1CNC1C(C=2C=CC=CC=2)NC2CCCCCC2C1 NHEGGUSCXQEJNO-UHFFFAOYSA-N 0.000 description 1
- GGNXNWSIEHNTPE-UHFFFAOYSA-N n-[(5-fluoro-2-methoxyphenyl)methyl]-2-phenyl-2,3,4,5,5a,6,7,8,9,9a-decahydro-1h-benzo[b]azepin-3-amine Chemical compound COC1=CC=C(F)C=C1CNC1C(C=2C=CC=CC=2)NC2CCCCC2CC1 GGNXNWSIEHNTPE-UHFFFAOYSA-N 0.000 description 1
- SPQCDQOWMJOJAC-UHFFFAOYSA-N n-[(5-fluoro-2-methoxyphenyl)methyl]-3-phenyl-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinolin-4-amine Chemical compound COC1=CC=C(F)C=C1CNC1C(C=2C=CC=CC=2)NCC2CCCCC21 SPQCDQOWMJOJAC-UHFFFAOYSA-N 0.000 description 1
- PPYSVALBTMOJGO-UHFFFAOYSA-N n-[(5-fluoro-2-methoxyphenyl)methyl]-3-phenyl-1,2,3,4,5,5a,6,7,8,8a-decahydrocyclopenta[c]azepin-4-amine Chemical compound COC1=CC=C(F)C=C1CNC1C(C=2C=CC=CC=2)NCC2CCCC2C1 PPYSVALBTMOJGO-UHFFFAOYSA-N 0.000 description 1
- IQFHFQFXIQIXMA-UHFFFAOYSA-N n-[(5-fluoro-2-methoxyphenyl)methyl]-3-phenyl-2,3,4,4a,5,6,7,7a-octahydro-1h-cyclopenta[c]pyridin-4-amine Chemical compound COC1=CC=C(F)C=C1CNC1C(C=2C=CC=CC=2)NCC2CCCC21 IQFHFQFXIQIXMA-UHFFFAOYSA-N 0.000 description 1
- XGQZOXOCKBSERX-UHFFFAOYSA-N n-[(5-fluoro-2-methoxyphenyl)methyl]-3-phenyl-2,3,4,4a,5,6,7,8,9,9a-decahydro-1h-cyclohepta[c]pyridin-4-amine Chemical compound COC1=CC=C(F)C=C1CNC1C(C=2C=CC=CC=2)NCC2CCCCCC21 XGQZOXOCKBSERX-UHFFFAOYSA-N 0.000 description 1
- YRAMTUYMGHLSMV-UHFFFAOYSA-N n-[(5-fluoro-2-methoxyphenyl)methyl]-4-phenyl-5-azabicyclo[5.1.0]octan-3-amine Chemical compound COC1=CC=C(F)C=C1CNC1C(C=2C=CC=CC=2)NCC2CC2C1 YRAMTUYMGHLSMV-UHFFFAOYSA-N 0.000 description 1
- ZCDYVHLFQGBVBQ-UHFFFAOYSA-N n-[(5-fluoro-2-methoxyphenyl)methyl]-5-phenyl-6-azabicyclo[5.5.0]dodecan-4-amine Chemical compound COC1=CC=C(F)C=C1CNC1C(C=2C=CC=CC=2)NC2CCCCCC2CC1 ZCDYVHLFQGBVBQ-UHFFFAOYSA-N 0.000 description 1
- NZNDBNGPPJVBNZ-UHFFFAOYSA-N n-[(5-tert-butyl-2-methoxyphenyl)methyl]-2-phenyl-1,2,3,4,4a,5,6,7,8,8a-decahydroquinolin-3-amine Chemical compound COC1=CC=C(C(C)(C)C)C=C1CNC1C(C=2C=CC=CC=2)NC2CCCCC2C1 NZNDBNGPPJVBNZ-UHFFFAOYSA-N 0.000 description 1
- RBFKRBJXNGPGSA-UHFFFAOYSA-N n-[(5-tert-butyl-2-methoxyphenyl)methyl]-2-phenyl-2,3,3a,4,5,6,7,7a-octahydro-1h-indol-3-amine Chemical compound COC1=CC=C(C(C)(C)C)C=C1CNC1C(C=2C=CC=CC=2)NC2CCCCC21 RBFKRBJXNGPGSA-UHFFFAOYSA-N 0.000 description 1
- ULRAKBTVRYVVHZ-UHFFFAOYSA-N n-[(5-tert-butyl-2-methoxyphenyl)methyl]-2-phenyl-2,3,3a,4,6,6a-hexahydro-1h-furo[3,4-b]pyrrol-3-amine Chemical compound COC1=CC=C(C(C)(C)C)C=C1CNC1C(C=2C=CC=CC=2)NC2COCC21 ULRAKBTVRYVVHZ-UHFFFAOYSA-N 0.000 description 1
- RZJXMQDBDHKXED-UHFFFAOYSA-N n-[(5-tert-butyl-2-propan-2-yloxyphenyl)methyl]-2-phenyl-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[b]pyrrol-3-amine Chemical compound CC(C)OC1=CC=C(C(C)(C)C)C=C1CNC1C(C=2C=CC=CC=2)NC2CCCC21 RZJXMQDBDHKXED-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical class C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Electroluminescent Light Sources (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Eye Examination Apparatus (AREA)
- Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59042390A | 1990-09-28 | 1990-09-28 | |
| US590,423 | 1990-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1060285A true CN1060285A (zh) | 1992-04-15 |
Family
ID=24362216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN91109446A Pending CN1060285A (zh) | 1990-09-28 | 1991-09-27 | 含氮非芳香杂环的稠环类似物 |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0550635B1 (enExample) |
| JP (1) | JPH0772175B2 (enExample) |
| CN (1) | CN1060285A (enExample) |
| AT (1) | ATE121389T1 (enExample) |
| AU (1) | AU651145B2 (enExample) |
| BR (1) | BR9106905A (enExample) |
| CA (1) | CA2089736A1 (enExample) |
| CZ (1) | CZ387492A3 (enExample) |
| DE (1) | DE69109125T2 (enExample) |
| DK (1) | DK0550635T3 (enExample) |
| ES (1) | ES2071334T3 (enExample) |
| FI (1) | FI931370L (enExample) |
| HU (1) | HUT68667A (enExample) |
| IE (1) | IE66042B1 (enExample) |
| IL (1) | IL99525A0 (enExample) |
| MX (1) | MX9101274A (enExample) |
| NO (1) | NO931151D0 (enExample) |
| PT (1) | PT99064A (enExample) |
| TW (1) | TW199144B (enExample) |
| WO (1) | WO1992006079A1 (enExample) |
| YU (1) | YU159291A (enExample) |
| ZA (1) | ZA917744B (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104610146A (zh) * | 2015-01-23 | 2015-05-13 | 常州大学 | 一种3-氮杂二环[5,1,0]-7-醛及合成方法 |
| CN105330588A (zh) * | 2015-10-16 | 2016-02-17 | 辽宁中医药大学 | 马齿苋中新生物碱Oleracone及其提取分离方法 |
| CN113121427A (zh) * | 2021-03-19 | 2021-07-16 | 广东工业大学 | 一种喹啉类衍生物及其制备方法和应用 |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5716965A (en) * | 1991-05-22 | 1998-02-10 | Pfizer Inc. | Substituted 3-aminoquinuclidines |
| ES2092113T3 (es) * | 1991-06-20 | 1996-11-16 | Pfizer | Derivados fluoroalcoxibencilamino de heterociclos que contienen nitrogeno. |
| TW202432B (enExample) * | 1991-06-21 | 1993-03-21 | Pfizer | |
| MY110227A (en) * | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
| EP0533280B2 (en) * | 1991-09-20 | 2004-12-01 | Glaxo Group Limited | Novel medical use for tachykinin antagonists |
| HUT70741A (en) * | 1991-11-12 | 1995-10-30 | Pfizer | Acyclic ethylenediamine derivatives as substance p receptor antagonists |
| EP0641328B1 (en) * | 1992-05-18 | 2001-11-21 | Pfizer Inc. | Bridged aza-bicyclic derivatives as substance p antagonists |
| US6048859A (en) | 1992-06-29 | 2000-04-11 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
| US5637699A (en) * | 1992-06-29 | 1997-06-10 | Merck & Co., Inc. | Process for preparing morpholine tachykinin receptor antagonists |
| US5719147A (en) * | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
| JPH07506379A (ja) * | 1992-08-04 | 1995-07-13 | ファイザー・インコーポレーテッド | 物質ｐ受容体アンタゴニストとしての３−ベンジルアミノ−２−フェニル−ピペリジン |
| GB9216911D0 (en) * | 1992-08-10 | 1992-09-23 | Merck Sharp & Dohme | Therapeutic agents |
| ATE208376T1 (de) * | 1992-08-19 | 2001-11-15 | Pfizer | Substituierte benzylamin-stickstoff enthaltende nichtaromatische heterocyclen |
| US5387595A (en) * | 1992-08-26 | 1995-02-07 | Merck & Co., Inc. | Alicyclic compounds as tachykinin receptor antagonists |
| US5344830A (en) * | 1992-12-10 | 1994-09-06 | Merck & Co., Inc. | N,N-diacylpiperazine tachykinin antagonists |
| JP2722279B2 (ja) * | 1992-12-10 | 1998-03-04 | ファイザー・インク． | アミノメチレンで置換した非芳香族複素環式化合物及びサブスタンスｐのアンタゴニストとしての使用 |
| US5830854A (en) * | 1992-12-14 | 1998-11-03 | Merck Sharp & Dohme, Limited | Method of treating cystic fibrosis using a tachykinin receptor antagonist |
| US5340826A (en) * | 1993-02-04 | 1994-08-23 | Pfizer Inc. | Pharmaceutical agents for treatment of urinary incontinence |
| US5393762A (en) * | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
| US5854262A (en) * | 1993-10-07 | 1998-12-29 | Pfizer Inc. | Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists |
| US5610165A (en) * | 1994-02-17 | 1997-03-11 | Merck & Co., Inc. | N-acylpiperidine tachykinin antagonists |
| TW385308B (en) * | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
| TW397825B (en) * | 1994-10-14 | 2000-07-11 | Novartis Ag | Aroyl-piperidine derivatives |
| FR2725900B1 (fr) * | 1994-10-21 | 1997-07-18 | Sanofi Sa | Utilisation d'antagonistes des recepteurs nk1 pour la preparation de medicaments a action cardioregulatrice |
| TW458774B (en) | 1995-10-20 | 2001-10-11 | Pfizer | Antiemetic pharmaceutical compositions |
| US6245817B1 (en) | 1997-02-14 | 2001-06-12 | Bayer Corporation | NPY5 receptor antagonists and methods for using same |
| WO1998035944A1 (en) * | 1997-02-14 | 1998-08-20 | Bayer Corporation | Amides as npy5 receptor antagonists |
| US6048900A (en) | 1998-02-13 | 2000-04-11 | Bayer Corporation | Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists |
| JP2000510164A (ja) * | 1997-02-14 | 2000-08-08 | バイエル・コーポレーシヨン | 選択的神経ペプチドｙ受容体アンタゴニストとしてのアミド誘導体 |
| US7163949B1 (en) | 1999-11-03 | 2007-01-16 | Amr Technology, Inc. | 4-phenyl substituted tetrahydroisoquinolines and use thereof |
| MXPA02004330A (es) | 1999-11-03 | 2004-07-30 | Albany Molecular Res Inc | Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina.. |
| CZ20023213A3 (cs) * | 2000-04-10 | 2003-12-17 | Pfizer Products Inc. | Benzoamidové piperidinové sloučeniny a příbuzné sloučeniny |
| US7119207B2 (en) | 2000-04-10 | 2006-10-10 | Pfizer Inc | Benzoamide piperidine containing compounds and related compounds |
| CN100430401C (zh) | 2000-07-11 | 2008-11-05 | Amr科技公司 | 新的4-苯基取代的四氢异喹啉类化合物及其治疗用途 |
| WO2002030888A2 (en) * | 2000-10-10 | 2002-04-18 | Calyx Therapeutics, Inc. | Tricyclic compounds and uses thereof |
| CN103880827B (zh) | 2004-07-15 | 2017-01-04 | 阿尔巴尼分子研究公司 | 芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和血清素的重摄取的应用 |
| EP1888050B1 (en) | 2005-05-17 | 2012-03-21 | Merck Sharp & Dohme Ltd. | cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer |
| DE102005027168A1 (de) * | 2005-06-13 | 2006-12-14 | Merck Patent Gmbh | Tetrahydrochinoline |
| UA95454C2 (uk) | 2005-07-15 | 2011-08-10 | Амр Текнолоджи, Інк. | Арил- і гетероарилзаміщені тетрагідробензазепіни і їх застосування для блокування зворотного захоплення норепінефрину, допаміну і серотоніну |
| BRPI0616463A2 (pt) | 2005-09-29 | 2011-06-21 | Merck & Co Inc | composto, composição farmacêutica, e, uso de um composto |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| GB0617867D0 (en) * | 2006-09-11 | 2006-10-18 | Glaxo Group Ltd | Chemical compounds |
| EP2698157B1 (en) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| RS51780B (sr) | 2007-01-10 | 2011-12-31 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. | Indazoli supstituisani amidom kao inhibitori poli(adp-riboza)polimeraze (parp) |
| WO2008090114A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
| JP5319518B2 (ja) | 2007-04-02 | 2013-10-16 | Ｍｓｄ株式会社 | インドールジオン誘導体 |
| WO2009002495A1 (en) | 2007-06-27 | 2008-12-31 | Merck & Co., Inc. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| GB0716573D0 (en) * | 2007-08-24 | 2007-10-03 | Glaxo Group Ltd | Chemical compounds |
| AU2009222122A1 (en) | 2008-03-03 | 2009-09-11 | Tiger Pharmatech | Tyrosine kinase inhibitors |
| GB0804326D0 (en) * | 2008-03-07 | 2008-04-16 | Glaxo Group Ltd | Novel compounds |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| AR071997A1 (es) | 2008-06-04 | 2010-07-28 | Bristol Myers Squibb Co | Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina |
| UA105182C2 (ru) | 2008-07-03 | 2014-04-25 | Ньюрексон, Інк. | Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность |
| EP2413932A4 (en) | 2009-04-01 | 2012-09-19 | Merck Sharp & Dohme | HAMMER OF ACT ACTIVITY |
| KR101830447B1 (ko) | 2009-05-12 | 2018-02-20 | 알바니 몰레큘라 리써치, 인크. | 7-(［1,2,4］트리아졸로［1,5-α］피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도 |
| EP2429295B1 (en) | 2009-05-12 | 2013-12-25 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
| US8815894B2 (en) | 2009-05-12 | 2014-08-26 | Bristol-Myers Squibb Company | Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
| UA109417C2 (uk) | 2009-10-14 | 2015-08-25 | Мерк Шарп Енд Доме Корп. | ЗАМІЩЕНІ ПІПЕРИДИНИ, ЯКІ ПІДВИЩУЮТЬ АКТИВНІСТЬ p53, І ЇХ ЗАСТОСУВАННЯ |
| US8999957B2 (en) | 2010-06-24 | 2015-04-07 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as ERK inhibitors |
| CN103068980B (zh) | 2010-08-02 | 2017-04-05 | 瑟纳治疗公司 | 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制 |
| LT2606134T (lt) | 2010-08-17 | 2019-07-25 | Sirna Therapeutics, Inc. | Hepatito b viruso (hbv) geno raiškos slopinimas, tarpininkaujant rnr interferencijai naudojant mažą interferuojančią nukleorūgštį (sina) |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| EP2615916B1 (en) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel erk inhibitors |
| EP2632472B1 (en) | 2010-10-29 | 2017-12-13 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina) |
| US9351965B2 (en) | 2010-12-21 | 2016-05-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| WO2012143879A1 (en) | 2011-04-21 | 2012-10-26 | Piramal Healthcare Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
| US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
| EP3453762B1 (en) | 2012-05-02 | 2021-04-21 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
| EP2900241B1 (en) | 2012-09-28 | 2018-08-08 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| EP3610890A1 (en) | 2012-11-14 | 2020-02-19 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| SI2925888T1 (en) | 2012-11-28 | 2018-02-28 | Merck Sharp & Dohme Corp. | Compounds and methods for the treatment of cancer |
| TW201429969A (zh) | 2012-12-20 | 2014-08-01 | Merck Sharp & Dohme | 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶 |
| EP2951180B1 (en) | 2013-01-30 | 2018-05-02 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| EP3525785B1 (en) | 2016-10-12 | 2025-08-27 | Merck Sharp & Dohme LLC | Kdm5 inhibitors |
| WO2019094312A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP3706742B1 (en) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP3833668B1 (en) | 2018-08-07 | 2025-03-19 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| US12173026B2 (en) | 2018-08-07 | 2024-12-24 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3452026A (en) * | 1966-03-15 | 1969-06-24 | Bristol Myers Co | Substituted 1,2,3,4-tetrahydroquinolines |
| FR1555552A (enExample) * | 1967-07-05 | 1969-01-31 | ||
| US4198415A (en) * | 1979-01-22 | 1980-04-15 | Eli Lilly And Company | Prolactin inhibiting octahydro pyrazolo[3,4-g]quinolines |
| MX18467A (es) * | 1988-11-23 | 1993-07-01 | Pfizer | Agentes terapeuticos de quinuclidinas |
-
1991
- 1991-08-20 EP EP91918058A patent/EP0550635B1/en not_active Expired - Lifetime
- 1991-08-20 AU AU87463/91A patent/AU651145B2/en not_active Expired - Fee Related
- 1991-08-20 FI FI931370A patent/FI931370L/fi not_active Application Discontinuation
- 1991-08-20 CZ CS923874A patent/CZ387492A3/cs unknown
- 1991-08-20 WO PCT/US1991/005776 patent/WO1992006079A1/en not_active Ceased
- 1991-08-20 DK DK91918058.8T patent/DK0550635T3/da active
- 1991-08-20 DE DE69109125T patent/DE69109125T2/de not_active Expired - Fee Related
- 1991-08-20 ES ES91918058T patent/ES2071334T3/es not_active Expired - Lifetime
- 1991-08-20 CA CA002089736A patent/CA2089736A1/en not_active Abandoned
- 1991-08-20 JP JP3517076A patent/JPH0772175B2/ja not_active Expired - Fee Related
- 1991-08-20 BR BR919106905A patent/BR9106905A/pt not_active Application Discontinuation
- 1991-08-20 HU HU9300898A patent/HUT68667A/hu unknown
- 1991-08-20 AT AT91918058T patent/ATE121389T1/de not_active IP Right Cessation
- 1991-08-23 TW TW080106710A patent/TW199144B/zh active
- 1991-09-19 IL IL99525A patent/IL99525A0/xx unknown
- 1991-09-26 MX MX9101274A patent/MX9101274A/es unknown
- 1991-09-26 PT PT99064A patent/PT99064A/pt not_active Application Discontinuation
- 1991-09-27 CN CN91109446A patent/CN1060285A/zh active Pending
- 1991-09-27 YU YU159291A patent/YU159291A/sh unknown
- 1991-09-27 IE IE339691A patent/IE66042B1/en not_active IP Right Cessation
- 1991-09-27 ZA ZA917744A patent/ZA917744B/xx unknown
-
1993
- 1993-03-26 NO NO931151A patent/NO931151D0/no unknown
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104610146A (zh) * | 2015-01-23 | 2015-05-13 | 常州大学 | 一种3-氮杂二环[5,1,0]-7-醛及合成方法 |
| CN105330588A (zh) * | 2015-10-16 | 2016-02-17 | 辽宁中医药大学 | 马齿苋中新生物碱Oleracone及其提取分离方法 |
| CN105330588B (zh) * | 2015-10-16 | 2017-09-26 | 辽宁中医药大学 | 马齿苋中生物碱Oleracone及其提取分离方法 |
| CN113121427A (zh) * | 2021-03-19 | 2021-07-16 | 广东工业大学 | 一种喹啉类衍生物及其制备方法和应用 |
| CN113121427B (zh) * | 2021-03-19 | 2022-04-01 | 广东工业大学 | 一种喹啉类衍生物及其制备方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| IE66042B1 (en) | 1995-12-13 |
| AU651145B2 (en) | 1994-07-14 |
| YU159291A (sh) | 1994-01-20 |
| EP0550635B1 (en) | 1995-04-19 |
| PT99064A (pt) | 1992-08-31 |
| IL99525A0 (en) | 1992-08-18 |
| ES2071334T3 (es) | 1995-06-16 |
| BR9106905A (pt) | 1993-08-17 |
| DE69109125D1 (de) | 1995-05-24 |
| HU9300898D0 (en) | 1993-06-28 |
| IE913396A1 (en) | 1992-04-08 |
| DE69109125T2 (de) | 1995-09-28 |
| ATE121389T1 (de) | 1995-05-15 |
| EP0550635A1 (en) | 1993-07-14 |
| NO931151L (no) | 1993-03-26 |
| AU8746391A (en) | 1992-04-28 |
| HUT68667A (en) | 1995-07-28 |
| NO931151D0 (no) | 1993-03-26 |
| TW199144B (enExample) | 1993-02-01 |
| FI931370A7 (fi) | 1993-03-26 |
| FI931370A0 (fi) | 1993-03-26 |
| CA2089736A1 (en) | 1992-03-29 |
| JPH06501267A (ja) | 1994-02-10 |
| DK0550635T3 (da) | 1995-09-04 |
| MX9101274A (es) | 1992-05-04 |
| ZA917744B (en) | 1993-03-29 |
| WO1992006079A1 (en) | 1992-04-16 |
| JPH0772175B2 (ja) | 1995-08-02 |
| CZ387492A3 (en) | 1994-02-16 |
| FI931370L (fi) | 1993-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1060285A (zh) | 含氮非芳香杂环的稠环类似物 | |
| CN1056373C (zh) | 含氮杂环类化合物的氟代烷氧基苄氨基衍生物的制备方法 | |
| CN1100534C (zh) | 2－(1h－4(5)－咪唑基环丙基衍生物及含该衍生物的药物组合物和其制备方法 | |
| CN1045595C (zh) | 合成3－氨基哌啶衍生物的中间体的制备方法 | |
| CN1157392C (zh) | 在尼古丁ach受体上作为胆碱能配体的8-氮杂双环(3,2,1)辛-2-烯以及辛烷衍生物 | |
| CN1037348C (zh) | 取代的5－(2－((2－芳基－2－羟乙基)氨基)丙基)－1,3－苯并间二氧杂环戊烯的制备方法 | |
| CN1036652C (zh) | 碱式季酰胺，其制备方法及其药物组合物 | |
| CN1032209C (zh) | 抗局部缺血剂2-呱啶子基-1-链烷醇衍生物的制备方法 | |
| CN1058405A (zh) | 奎宁环衍生物 | |
| CN1688544A (zh) | 作为蕈毒碱受体拮抗剂的含氟代和磺酰氨基的3,6－二取代的氮杂双环(3.1.0)己烷衍生物 | |
| CN1211982A (zh) | 托烷衍生物,其制备和应用 | |
| CN1859904A (zh) | 用于治疗阿尔茨海默氏病的苄醚和苄氨基β－分泌酶抑制剂 | |
| CN1094723A (zh) | 羧酰胺衍生物 | |
| CN1118467C (zh) | 1,3,8－三氮杂螺[4,5]癸－4－酮衍生物 | |
| CN1067889A (zh) | 取代的n-(1-烷基-3-羟基-4-哌啶基)苯甲酰胺的制备方法 | |
| CN1053923A (zh) | 具有神经保护作用的3-哌啶子基-4-羟基苯并二氯吡喃衍生物 | |
| CN1859914A (zh) | 苯基吡咯烷醚速激肽受体拮抗剂 | |
| CN1226825A (zh) | 胺化合物用于制备阻止肿瘤细胞增殖的药物 | |
| CN1022322C (zh) | 稠合吡唑3-氧代-丙腈衍生物的制备方法 | |
| CN1639121A (zh) | 具有鸦片样受体亲合性的3－氮杂二环并(3.1.0)己烷衍生物 | |
| CN1166640C (zh) | 经取代的1,2,3,4,5,6-六氢-2,6-亚甲基-3-苯并吖辛因-10-醇,其制法及作为药物组合物的用途 | |
| CN1050022A (zh) | 去氢环黄皮酰胺衍生物的制备方法 | |
| CN1039591A (zh) | 烯胺季铵化合物和制造方法及其在肌肉松弛剂中的应用 | |
| CN1665506A (zh) | 作为ccr－3受体拮抗剂ⅸ的2,5－取代的嘧啶衍生物 | |
| CN1349527A (zh) | 取代的苯并内酰胺化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |